JFS Wealth Advisors LLC Has $120,000 Stock Position in GSK plc (NYSE:GSK)

JFS Wealth Advisors LLC cut its position in GSK plc (NYSE:GSK) by 87.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,561 shares of the pharmaceutical company’s stock after selling 25,865 shares during the quarter. JFS Wealth Advisors LLC’s holdings in GSK were worth $120,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of GSK. Eastern Bank bought a new position in shares of GSK in the third quarter worth about $26,000. Sunbelt Securities Inc. increased its position in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Indiana Trust & Investment Management Co boosted its position in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in shares of GSK in the fourth quarter worth $26,000. Finally, Concord Wealth Partners increased its position in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 547 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 1.0 %

Shares of GSK opened at $36.20 on Tuesday. The company has a current ratio of 0.78, a quick ratio of 0.53 and a debt-to-equity ratio of 1.12. The stock has a market cap of $75.02 billion, a PE ratio of 22.76, a PEG ratio of 1.42 and a beta of 0.64. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The stock has a 50 day simple moving average of $34.42 and a 200-day simple moving average of $37.44.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, sell-side analysts predict that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.34%. GSK’s payout ratio is 93.08%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.